Regulatory & Reimbursement
Colorectal Cancer Liquid Biopsy: CMS Proposes Coverage Thresholds But Excludes First-to-Market Test
Medicare's recently proposed NCD for blood-based colorectal cancer screening tests may be good news for the field, which has been challenged by non-compliance with existing screening methods. However, it excludes coverage for the NCD’s initiator, Epigenomics, and its Epi proColon test. The company is hoping for better news in the upcoming final policy.
Read Article